Literature DB >> 15140994

Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo.

Daniel A Muruve1, Matthew J Cotter, Anne K Zaiss, Lindsay R White, Qiang Liu, Trevor Chan, Sharon A Clark, P Joel Ross, Robert A Meulenbroek, Gunhild M Maelandsmo, Robin J Parks.   

Abstract

Helper-dependent adenovirus (HD-Ad) vectors with all adenoviral genes deleted mediate very long-term expression of therapeutic transgenes in a variety of animal models of disease. These vectors are associated with reduced toxicity and improved safety relative to traditional early region 1 deletion first-generation Ad (FG-Ad) vectors. Many studies have clearly demonstrated that FG-Ad vectors induce innate and adaptive immune responses in vivo; however, a comprehensive analysis of host immune responses to HD-Ad vectors has not yet been performed. In DBA/2 mice, intravenous injection of HD-Ad vectors encoding LacZ (HD-AdLacZ) or a murine secreted alkaline phosphatase (HD-AdSEAP) induced an early expression of inflammatory cytokine and chemokine genes in the liver, including interferon-inducible protein 10, macrophage inflammatory protein 2, and tumor necrosis factor alpha, and were expressed in a pattern similar to that induced by FG-Ad vectors encoding AdSEAP. Like AdSEAP, and consistent with the pattern of cellular gene expression, HD-AdLacZ and HD-AdSEAP induced the recruitment of CD11b-positive leukocytes to the transduced liver within hours of administration. AdSEAP also induced a second phase of liver inflammation, consisting of inflammatory gene expression and CD3-positive lymphocytic infiltrates 7 days posttransduction. In contrast, beyond 24 h no infiltrates or expression of inflammatory genes was detected in the livers of mice receiving HD-AdSEAP. Despite the lack of liver inflammation at 7 days, Ad-specific cytotoxic T lymphocytes could be detected in mice receiving HD-AdSEAP. This lack of liver inflammation was not due to reduced transduction since levels of transgene expression and the amounts of vector DNA in the liver were equivalent in mice receiving HD-AdSEAP and AdSEAP. These results demonstrate that HD-Ad vectors induce intact innate but attenuated adaptive immune responses in vivo.

Entities:  

Mesh:

Year:  2004        PMID: 15140994      PMCID: PMC415814          DOI: 10.1128/JVI.78.11.5966-5972.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system.

Authors:  L Zou; H Zhou; L Pastore; K Yang
Journal:  Mol Ther       Date:  2000-08       Impact factor: 11.454

2.  Cre levels limit packaging signal excision efficiency in the Cre/loxP helper-dependent adenoviral vector system.

Authors:  Philip Ng; Carole Evelegh; Derek Cummings; Frank L Graham
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Adenovirus vector-induced inflammation: capsid-dependent induction of the C-C chemokine RANTES requires NF-kappa B.

Authors:  Gloria P Bowen; Stephanie L Borgland; Mindy Lam; Towia A Libermann; Norman C W Wong; Daniel A Muruve
Journal:  Hum Gene Ther       Date:  2002-02-10       Impact factor: 5.695

4.  Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages.

Authors:  Y Zhang; N Chirmule; G P Gao; R Qian; M Croyle; B Joshi; J Tazelaar; J M Wilson
Journal:  Mol Ther       Date:  2001-05       Impact factor: 11.454

5.  Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.

Authors:  M A Schnell; Y Zhang; J Tazelaar; G P Gao; Q C Yu; R Qian; S J Chen; A N Varnavski; C LeClair; S E Raper; J M Wilson
Journal:  Mol Ther       Date:  2001-05       Impact factor: 11.454

6.  Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination.

Authors:  P Umaña; C A Gerdes; D Stone; J R Davis; D Ward; M G Castro; P R Lowenstein
Journal:  Nat Biotechnol       Date:  2001-06       Impact factor: 54.908

7.  Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain.

Authors:  C E Thomas; D Birkett; I Anozie; M G Castro; P R Lowenstein
Journal:  Mol Ther       Date:  2001-01       Impact factor: 11.454

8.  Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector.

Authors:  I H Kim; A Józkowicz; P A Piedra; K Oka; L Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

9.  Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors.

Authors:  L Pastore; N Morral; H Zhou; R Garcia; R J Parks; S Kochanek; F L Graham; B Lee; A L Beaudet
Journal:  Hum Gene Ther       Date:  1999-07-20       Impact factor: 5.695

10.  Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I.

Authors:  Sophie Van Linthout; Désiré Collen; Bart De Geest
Journal:  Hum Gene Ther       Date:  2002-05-01       Impact factor: 5.695

View more
  86 in total

Review 1.  Cocaine hydrolase gene therapy for cocaine abuse.

Authors:  Stephen Brimijoin; Yang Gao
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5.

Authors:  Eric Ehrke-Schulz; Wenli Zhang; Maren Schiwon; Thorsten Bergmann; Manish Solanki; Jing Liu; Philip Boehme; Theo Leitner; Anja Ehrhardt
Journal:  J Vis Exp       Date:  2016-01-28       Impact factor: 1.355

Review 3.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

4.  Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

Review 6.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

7.  One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.

Authors:  Carlos Barcia; Maximiliano Jimenez-Dalmaroni; Kurt M Kroeger; Mariana Puntel; Alison J Rapaport; Daniel Larocque; Gwendalyn D King; Stephen A Johnson; Chunyan Liu; Weidong Xiong; Marianela Candolfi; Sonali Mondkar; Philip Ng; Donna Palmer; Maria G Castro; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2007-09-25       Impact factor: 11.454

Review 8.  Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors.

Authors:  N Brunetti-Pierri; P Ng
Journal:  Gene Ther       Date:  2008-02-21       Impact factor: 5.250

Review 9.  Targeted gene insertion for molecular medicine.

Authors:  Katrin Voigt; Zsuzsanna Izsvák; Zoltán Ivics
Journal:  J Mol Med (Berl)       Date:  2008-07-08       Impact factor: 4.599

Review 10.  Innate immune recognition of viruses and viral vectors.

Authors:  Xiaopei Huang; Yiping Yang
Journal:  Hum Gene Ther       Date:  2009-04       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.